Aprinoia Therapeutics (Aprinoia Therapeutics) FCF Yield % : 0.00 (As of May. 01, 2024)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Aprinoia Therapeutics's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $0.00 Mil. Therefore, Aprinoia Therapeutics's FCF Yield % for today is 0.00%.

The historical rank and industry rank for Aprinoia Therapeutics's FCF Yield % or its related term are showing as below:

APRI's FCF Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: -14.81
* Ranked among companies with meaningful FCF Yield % only.

Aprinoia Therapeutics's FCF Margin % for the quarter that ended in Jun. 2023 was -61.68%.

Aprinoia Therapeutics FCF Yield % Historical Data

The historical data trend for Aprinoia Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics FCF Yield % Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

FCF Yield %

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
FCF Yield %	-	-	-	-

Competitive Comparison of Aprinoia Therapeutics's FCF Yield %

For the Biotechnology subindustry, Aprinoia Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's FCF Yield % falls into.

Aprinoia Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Aprinoia Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-19.253	/	0
	=	N/A%

Aprinoia Therapeutics's annualized FCF Yield % for the quarter that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-5.572	*	2	/	0
	=	N/A%

Aprinoia Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Aprinoia Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines